Antibacterial, antifungal, antiviral, and antispore paints

抗菌、抗真菌、抗病毒和抗孢子涂料

基本信息

  • 批准号:
    8207166
  • 负责人:
  • 金额:
    $ 9.54万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-12-22 至 2012-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): There is a fast growing need for antimicrobial paints and coatings to improve microbial quality in residential, commercial, institutional, and industrial applications so as to control the growth of mold and/or reduce the risk of healthcare-associated infections or community-acquired infections. A number of paint products on the market claim "antimicrobial" functions. However, the current products have significant shortfalls, including weak antimicrobial activities, risk of microbial resistance, and difficulty in monitoring and extending the antimicrobial functions once the paints are applied. To solve these problems, in this proposed project, we will use polymeric N-halamines, a class of widely used water and food disinfectants, as antimicrobial additives to provide biocidal effects against bacteria (including drug-resistant species), mold and other fungi species, viruses, and spores. An N-halamine is a compound containing one or more nitrogen-halogen covalent bonds. N-halamines have similar antimicrobial efficacy as hypochlorite bleach, but they are much more stable, none corrosive, with no reported cases of microbial resistance, and have a much less tendency to generate halogenated hydrocarbons. In our technology, a new N-halamine monomer developed in our lab, N-chloro-2,2,6,6- tetramethyl-4-piperidinyl acrylate (Cl-TMPA), will be polymerized to produce polymeric N-halamine latex emulsions. On adding a small amount of such emulsions into conventional water-based latex paint, the new paint will be able to provide potent antimicrobial activities against various microorganisms. The antimicrobial activity is anticipated to last for the lifetime of the paint under normal use. Challenging conditions (e.g., heavy soil, flooding, etc.) may consume more chlorine and thus shorten the antimicrobial duration. Nevertheless, the antimicrobial function of the new paints can be easily monitored by a simple potassium iodine/starch test. That is, polymeric N-halmines will react with potassium iodine to generate a dark blue color with starch. Thus, this test determines whether the paint still provides antimicrobial functions. If it shows that the antimicrobial function is lost, the polymeric N-halamine structures can be resumed by wiping the surface with diluted hypochlorite bleach to recharge the lost chlorine and regenerate the antimicrobial functions. The recharging can be repeated as needed. If successful, this technology will provide an innovative approach to protect high-touch, high-risk surfaces in a wide range of applications, which will have a broad and significant impact on health. This STTR Phase I study is designed to establish the feasibility and effectiveness of the new approach before continuation and expansion of the project. The specific aims of the proposed research are to: (1) create polymeric N-halamine latex emulsions; (2) mix the polymeric N-halamine latex emulsions with commercially important latex paints, and characterize the physical properties, antimicrobial performance, and biocompatibility of the new paints developed; and (3) preliminarily determine the cost of the new approach. PUBLIC HEALTH RELEVANCE: The unique features of the new paints include the broad antimicrobial spectrum against bacteria, mold and other fungi species, viruses, and spores, the ease in monitoring the antimicrobial activity, the rechargability of N-halamines if the antimicrobial function is accidentally lost, and the low risk of microbial resistance. These advantages make the new polymeric N-halamine-based antimicrobial paints an attractive candidate for protecting high-touch, high-risk surfaces in residential, commercial, institutional, industrial, and other related facilities. This STTR Phase I research will serve as the foundation for continuation and expansion of the project and finally commercialize the products to improve the microbial quality of a wide range of environmental surfaces, and this will have a broad and significant impact on health.
描述(由申请人提供):为了改善住宅、商业、机构和工业应用中的微生物质量,以控制霉菌的生长和/或降低与医疗保健相关的感染或社区获得性感染的风险,对抗菌油漆和涂料的需求正在快速增长。市场上的许多油漆产品都声称具有“抗菌”功能。然而,目前的产品存在明显的不足,包括抗菌活性弱,微生物耐药风险,以及一旦涂料应用后难以监测和扩展抗菌功能。为了解决这些问题,在本项目中,我们将使用高分子N-halamines作为抗菌添加剂,对细菌(包括耐药物种),霉菌和其他真菌物种,病毒和孢子提供生物杀灭作用。高分子N-halamines是一类广泛使用的水和食品消毒剂。n-卤胺是含有一个或多个氮卤共价键的化合物。n -卤胺具有与次氯酸盐漂白剂相似的抗菌功效,但它们更稳定,没有腐蚀性,没有微生物耐药性的报告,并且产生卤化碳氢化合物的倾向要小得多。在我们的技术中,我们实验室开发的一种新的N-halamine单体,n -氯-2,2,6,6-四甲基-4-胡椒酰丙烯酸酯(Cl-TMPA),将被聚合以生产聚合N-halamine乳胶乳液。在传统的水性乳胶漆中加入少量这种乳剂,这种新型涂料将能够对各种微生物提供有效的抗菌活性。在正常使用情况下,预计抗菌活性将持续整个油漆的使用寿命。具有挑战性的条件(例如,土壤重,洪水等)可能会消耗更多的氯,从而缩短抗菌持续时间。尽管如此,新涂料的抗菌功能可以通过简单的碘化钾/淀粉测试轻松监测。也就是说,聚合n -卤化物会与碘化钾反应,与淀粉一起产生深蓝色。因此,该测试确定涂料是否仍具有抗菌功能。如果显示抗菌功能丧失,可以用稀释的次氯酸漂白剂擦拭表面,以补充失去的氯并再生抗菌功能,从而恢复聚合n -卤胺结构。可以根据需要重复充电。如果成功,这项技术将提供一种创新的方法,在广泛的应用中保护高接触、高风险的表面,这将对健康产生广泛而重大的影响。这项STTR第一期研究旨在确定新方法的可行性和有效性,然后再进行工程的延续和扩展。提出的研究的具体目的是:(1)制造聚合物N-halamine乳胶乳液;(2)将聚合N-halamine乳胶乳液与重要的商业乳胶漆混合,并对新涂料的物理性能、抗菌性能和生物相容性进行表征;(3)初步确定新方法的成本。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Daniel S ENGEBRETSON其他文献

Daniel S ENGEBRETSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Daniel S ENGEBRETSON', 18)}}的其他基金

Antibacterial, antifungal, antiviral, and antispore paints
抗菌、抗真菌、抗病毒和抗孢子涂料
  • 批准号:
    8000009
  • 财政年份:
    2010
  • 资助金额:
    $ 9.54万
  • 项目类别:
Implanted Membranes for Characterization and Monitoring
用于表征和监测的植入膜
  • 批准号:
    6548078
  • 财政年份:
    2002
  • 资助金额:
    $ 9.54万
  • 项目类别:
Implanted Membranes for Characterization and Monitoring
用于表征和监测的植入膜
  • 批准号:
    6665210
  • 财政年份:
    2002
  • 资助金额:
    $ 9.54万
  • 项目类别:

相似海外基金

Is sialic acid recognition receptor a candidate molecule for diagnosis of allergic bronchopulmonary aspergillosis?
唾液酸识别受体是诊断过敏性支气管肺曲霉病的候选分子吗?
  • 批准号:
    20K07183
  • 财政年份:
    2020
  • 资助金额:
    $ 9.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of new experimental models to understand the genetic basis of allergic bronchopulmonary aspergillosis (ABPA)
开发新的实验模型以了解过敏性支气管肺曲霉病(ABPA)的遗传基础
  • 批准号:
    NC/P002390/1
  • 财政年份:
    2017
  • 资助金额:
    $ 9.54万
  • 项目类别:
    Fellowship
Airway inflamation in allergic bronchopulmonary aspergillosis and the use of Itraconazole
过敏性支气管肺曲霉病的气道炎症和伊曲康唑的使用
  • 批准号:
    nhmrc : 8201
  • 财政年份:
    2000
  • 资助金额:
    $ 9.54万
  • 项目类别:
    NHMRC Postgraduate Scholarships
ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS
过敏性支气管肺曲霉病
  • 批准号:
    4688612
  • 财政年份:
  • 资助金额:
    $ 9.54万
  • 项目类别:
ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS
过敏性支气管肺曲霉病
  • 批准号:
    3809780
  • 财政年份:
  • 资助金额:
    $ 9.54万
  • 项目类别:
ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS
过敏性支气管肺曲霉病
  • 批准号:
    3790909
  • 财政年份:
  • 资助金额:
    $ 9.54万
  • 项目类别:
ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS
过敏性支气管肺曲霉病
  • 批准号:
    3960685
  • 财政年份:
  • 资助金额:
    $ 9.54万
  • 项目类别:
AEROSOL ANTIGEN CHALLENGE IN ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS
过敏性支气管肺曲霉病中的气溶胶抗原挑战
  • 批准号:
    4701085
  • 财政年份:
  • 资助金额:
    $ 9.54万
  • 项目类别:
AEROSOL ANTIGEN CHALLENGE IN ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS
过敏性支气管肺曲霉病中的气溶胶抗原挑战
  • 批准号:
    3973552
  • 财政年份:
  • 资助金额:
    $ 9.54万
  • 项目类别:
ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS
过敏性支气管肺曲霉病
  • 批准号:
    3818343
  • 财政年份:
  • 资助金额:
    $ 9.54万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了